(TECX), a clinical-stage biotechnology company, on Thursday announced positive interim data from its ongoing Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...